[출처/시간] MT Newswires - 3:40 AM ET, 05/27/2026 03:40 AM EDT, 05/27/2026 (MT Newswires) -- AstraZeneca (AZN) said Wednesday the US Food and Drug Administration delayed the decision deadline for its new drug application regarding a combination breast cancer treatment to evaluate additional information. The regulator requested further details regarding the proposed use of camizestrant alongside a cyclin-dependent kinase inhibitor for treating speci
[출처/시간] MT Newswires - 3:40 AM ET, 05/27/2026
03:40 AM EDT, 05/27/2026 (MT Newswires) -- AstraZeneca (AZN) said Wednesday the US Food and Drug Administration delayed the decision deadline for its new drug application regarding a combination breast cancer treatment to evaluate additional information.
The regulator requested further details regarding the proposed use of camizestrant alongside a cyclin-dependent kinase inhibitor for treating specific advanced breast tumors, the company said.
The drugmaker submitted an extra effectiveness analysis to the authorities to support the approval request after a government advisory committee previously failed to reach a consensus regarding the clinical benefits of the therapy during an April meeting, AstraZeneca said.
The company also said a European regulatory panel recently recommended the drug combination for approval, while health officials in Japan continue to review the medication.
리포트 잘 봤습니다. 경쟁사 비교 차트가 한눈에 들어와서 좋네요. 다음 분기 가이던스가 어떻게 나올지 궁금합니다.
같은 섹터의 ETF 흐름도 함께 보면 더 좋을 것 같습니다.
의견 감사합니다. 곧 섹터 ETF 비교 차트를 별도 임베드로 추가할 예정입니다.